Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Information source: Novo Nordisk
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus, Type 2
Intervention: liraglutide (Drug); glibenclamide (Drug); placebo (Drug); placebo (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Novo Nordisk Official(s) and/or principal investigator(s):
Yasuyuki Katayama, MD, Study Director, Affiliation: Novo Nordisk Pharma Ltd.
Hiroko Terano, Study Director, Affiliation: Novo Nordisk Pharma Ltd.
Summary
This trial is conducted in Japan.
The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to
sulfonylurea (SU treatment), as assessed by HbA1C after 24 and 52 weeks in subjects with type
2 diabetes.
Clinical Details
Official title: Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: HbA1C
Secondary outcome: body weightSafety and tolerability Glycaemic control parameters HbA1C
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Type 2 diabetes
- Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight
weeks
- HbA1C greater than or equal to 7. 0% and less than 10. 0%
- BMI less than 35 kg/m2
Exclusion Criteria:
- Treatment with insulin within the last 12 weeks
- Treatment with any drug that could interfere with the glucose level
- Any serious medical condition
- Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Locations and Contacts
Osaka, Japan
Additional Information
Clinical Trials at Novo Nordisk
Starting date: October 2006
Ending date: April 2008
Last updated: February 13, 2008
|
